Indications for PIFELTRO:
In combination with other antiretroviral agents for HIV-1 infection in antiretroviral treatment-naïve adult patients.
≥18yrs: 100mg once daily. Concomitant rifabutin: 100mg twice daily (approx. 12hrs apart).
<18yrs: not established.
Concomitant strong CYP3A inducers (eg, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, St. John's wort): discontinue for ≥4wks prior to starting Pifeltro.
Immune reconstitution syndrome. ESRD or dialysis: not studied. Severe hepatic impairment (Child-Pugh C): not studied. Elderly. Pregnancy. Nursing mothers: not recommended.
Non-nucleoside reverse transcriptase inhibitor.
Concomitant efavirenz, etravirine, nevirapine: not recommended. May be antagonized by CYP3A inducers (see Contraindications). May be potentiated by CYP3A inhibitors.
Nausea, dizziness, headache, fatigue, diarrhea, abdominal pain, abnormal dreams.
To register pregnant patients to the Antiretroviral Pregnancy Registry, call (800) 258–4263.